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1. Introduction 
1.1. Historical Background of Induction Therapy 
The initial results of kidney transplantation were significantly affected by a high rate of 
acute rejection as well as significant perioperative morbidity. Historically, the 
armamentarium of the transplant physician consisted of glucocorticoids and azathioprine. 
Significant improvements in the science and understanding of kidney transplantation 
immunology have lead to the development of induction therapy agents. Early induction 
therapy agents possessed little specificity and delivered a broad spectrum of effects; 
however, their potent ability to prevent early acute rejection episodes led to their 
widespread use [1]. 
The extensive use of these formulations exposed their flaws. The cross-reactivity with 
hematopoietic cells revealed dose-limiting side effects including thrombocytopenia, anemia, 
and neutropenia [2, 3]. Moreover, the lack of standardized preparation led to variations in 
dosing. In addition, these formulations had significant antigenic properties as a result of 
using horse or rabbit based formulations, which lead to significant side effects, such as 
serum sickness, cytokine release syndrome, or even anaphylaxis [4-6].  
The development of specific, monoclonal antibodies by Kohler and Milstein circumvented 
many of the drawbacks of polyclonal formulations, including lack of specificity and 
variability in preparation [7]. Muromonab, or OKT3, was the first monoclonal antibody 
prepared from mouse specific for cluster of differentiation 3 (CD3) [8]. OKT3 was effective at 
specifically depleting T cells from the circulation, and became widely used as a valuable tool 
to combat acute rejection episodes [9, 10]. Nevertheless, these monoclonal formulations still 
maintained some of the similar side effect profile of the polyclonal formulations, including 
an antigenic response to the protein or cytokine release syndrome, which lead to limited 
dosing in some patients [11]. 
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The 1980’s marked an important era in transplantation with new advances in genetic 
engineering. Monoclonal antibodies became more sophisticated, targeting specific T cell 
populations and allowing blockade of T cell activation, such as the interleukin 2 receptor (IL-2R) 
or CD25 [12]. Moreover, the ability to avoid antigenic proteins by encoding genetic sequences of 
DNA binding sites of animal proteins onto human antibodies led to the development of 
chimeric monoclonal antibodies [13-15]. Using these techniques, soluble fusion proteins can be 
formed by merging nonantibody receptors with the Fc portion of antibodies. 
1.2. Antibodies 
Understanding the structure and function of antibodies is critical to understanding the 
efficacy of antibody induction therapy. Antibodies are composed of two identical heavy 
chains (either µ, γ, α, ε, or δ) and two identical light chains (either κ or λ). The heavy and 
light chain portions create two identical antigen binding sites (Fab fragment) which are held 
together by the common region, termed the Fc portion [16]. The type of heavy chain 
differentiates the immunoglobulin type as IgM, IgG, IgA, IgE, and IgD. In clinical 
transplantation, the IgG molecule is typically utilized, as it’s readily produced and 
structurally feasible to manipulate (Fig. 1). 
 
Figure 1. Basic antibody structure. Depicted is a standard IgG molecule. The heavy chains are colored 
in blue, while the light chains are colored in green. The yellow lines signify the disulfide bonds. 
Antibodies are present on the surface of B cells. Upon secretion into the serum, antibodies 
are able to neutralize circulating antigens. Antibodies maintain their effector functions 
irrespective of species. Antibodies are capable of various functions, including mimicking 
activating ligands of receptors and serving as receptor inhibitors by blocking the ligand 
binding site [17, 18]. In some instances, antibody binding can lead to both activation and 
inhibition by inducing surface molecule internalization, whereby the molecule is removed 
from the surface of the cell [19]. This results in a negligible net effect. A major limitation of 
antibody use is the inability to directly bind intracellular molecules. 
Antibodies have the ability to deplete target cells through two basic mechanisms. First, 
antibodies can activate the complement system resulting in complement-mediated lysis of 
target cells. Second, certain cells with Fc region receptors have the ability to phagocytose 
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cells covered with antibodies through a mechanism termed antibody-dependent cellular 
cytotoxicity (ADCC) (Fig.2). The efficacy with which this occurs depends upon the Fab 
fragment and the Fc region [20]. It is important to note that cells which have significantly 
matured, or memory cells, are somewhat resistant to antibody-dependent depletion 
mechanisms, possibly due to increased expression of anti-apoptotic or complement 
regulatory genes [21]. 
 
Figure 2. Antibody-dependent cellular cytotoxicity (ADCC). The Fc receptor on the macrophage is used 
to bind the constant Fc portion of antibodies to facilitate engulfment of cells coated with antibodies. 
1.3. Classifying induction therapy agents 
Induction therapy agents can be classified into two groups: depleting agents and non-
depleting agents (Table 1). This distinction is based on the ability to target specific antigens 
or cells, leading to a decrease in the total expression or cell count. Most depleting agents are 
relatively potent with potential for toxicity with prolonged administration, while non-
depleting agents are generally well-tolerated. In addition, the use of induction therapy 
agents has decreased the rates of acute rejection in the first 6 months compared to no 
induction therapy [22]. Although these short-term benefits appear promising, long-term 
outcomes, including patient and graft survival rates, have not been shown to be altered by 
the use of induction therapy, possibly the effect of long-term maintenance 
immunosuppressive therapy or even patient co-morbidities. 
The overall success of a kidney transplant is contingent on both surgical technique and 
potent immunosuppressive medications. Although induction therapy has not affected 
surgical morbidity, the rate of allograft thrombosis has been shown to be reduced in 
children with the use of induction agents [23, 24]. However, not all medications used are 
FDA-approved for induction therapy. Additionally, these medications are not without risks, 
including infectious complications and the development of post-transplant 
lymphoproliferative disorder (PTLD), which has been well-described with the use of OKT3 
and maintenance immunosuppression [25, 26]. Because of the effects of depleting agents on 
T cells, appropriate infectious prophylaxis should be instituted for all transplant recipients. 
In 1995 induction therapy was used in less than half of all kidney transplants in the United 
States, while 10 years later, approximately 70% of all kidney transplant recipients received 
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Agent Clonality Targets Dosing Halflife Duration of 
effects 
Cytokine 
Release 
Syndrome? 
rATG1 Polyclonal Various immune 
targets, especially 
T cells 
Multiple doses 
(POD2#0-4) 
29.8-37.7 
days 
Months to 
years 
Yes 
Basiliximab Monoclonal CD25 
(predominantly 
activated T cells) 
2 doses 
(POD2#0 & 4) 
7.2 days Weeks No 
Daclizumab Monoclonal CD25 
(predominantly 
activated T cells) 
Multiple doses 
(POD2#0, then 
every 2 weeks) 
20 days Weeks No 
Alemtuzumab Monoclonal CD52 (naïve T 
cells, some B cells, 
and monocytes) 
Typically 1 dose 
(POD2#0) 
12 days Months to 
years 
Yes (less 
than rATG1) 
1rabbit Antithymocyte globulin, 2post operative day 
Table 1. Pharmacological Comparison of Induction Therapy 
induction therapy [27]. Given the availability of various potent, specific induction agents in 
modern transplantation, the clinical dilemma lies in selecting the most appropriate agent for 
a given patient, taking into account co-morbidities, donor quality, immunological status, 
and planned immunosuppression maintenance therapy. 
2. Induction therapy agents 
2.1. Depleting agents 
2.1.1. Rabbit Antithymocyte globulin (rATG) 
2.1.1.1. Mechanism of Action 
Rabbit antithymocyte globulin (rATG) is a polyclonal heterologous antibody produced from 
immunizing rabbits with human thymocytes, which serve as the immunogens (Fig. 3) [28]. The 
rabbit serum is then gathered and purified to remove antibodies with potentially detrimental 
effects and only the IgG isotypes are collected. Despite these purification techniques, it is 
possible that the majority of antibodies in these formulations serve no therapeutic purpose [29, 
30]. When administered to humans, the rATG antibody formulations bind all antigens that the 
rabbits were exposed to during the immunization process. 
rATG binds multiple T cell surface antigens and receptors involved in antigen recognition, 
adhesion and costimulation, including CD2, CD3, CD4, CD5, CD8, CD28, CD45, and CD40L. 
In addition, rATG may also bind non-T cell molecules such as CD16, CD20, CD56, and the 
major histocompatibility molecules (class I and II) [28-30]. The depleting effect of rATG 
occurs within 24 hours of administration and can persist with a prolonged serum half-life of 
several weeks [31, 32]. The effects of lymphocyte depletion are persists for years following 
administration, as evidenced by selectively low CD4+ T cell counts [33, 34]. 
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Figure 3. Polyclonal antibodies. Polyclonal antibodies are non-specific and bind multiple antigens as 
shown in the figure. 
2.1.1.2. Clinical applications 
rATG has been approved for use as an induction agent and for the treatment of acute 
rejection in Europe since 1984 [35]. However, in the United States, it is only indicated for the 
treatment of acute rejection. Nevertheless, it is routinely administered as induction therapy 
in many centers in the United States. Although early studies demonstrated an increased 
infectious risk and post-transplant malignancy when administered in conjunction with 
cyclosporine [36], improvements in infectious prophylaxis and lower doses have 
significantly alleviated these risks. 
rATG administration improves early outcomes in kidney transplantation. Although the exact 
mechanism leading to this is unclear, rATG may minimize ischemia-reperfusion injury and 
potentially prevent the development of delayed graft function, which has been associated with 
poorer outcomes [37]. rATG has been used in patients at higher risk of developing delayed 
graft function, including recipients of donation after cardiac death donors, and recipients of 
extended criteria donors [38-40]. It is also administered in patients at higher immunologic risk, 
such as retransplants. Finally, it may help minimize the need for maintenance 
immunosuppression therapy facilitating early corticosteroid withdrawal [40, 41]. 
2.1.1.3. Adverse effects 
Patients treated with rATG may experience a variety of side effects. It has been associated 
with a syndrome called cytokine release syndrome (Fig. 4), which is common to many 
polyclonal antibody formulations. Patients may experience mild flu-like symptoms, such as 
fever, chills, nausea, urticaria, rash, and headache [32]. This occurs as a result of increased 
production of tumor necrosis factor-α, IL-1, and IL-6 [28, 32, 42]. Premedication with 
corticosteroids, antipyretics, and antihistamines can prevent or treat these flu-like 
symptoms. In some cases, patients may develop more severe shock-like reactions, such as 
dyspnea, severe hypotension, pulmonary edema, or even anaphylaxis. Although patients 
frequently experience the mild flu-like symptoms and not the more severe reactions, 
recipient co-morbid conditions, such as cardiac or pulmonary disease, should be considered 
when selecting rATG as an induction agent. Serum sickness has also been associated with 
rATG administration in up to 7-10% of patients [43, 44]. 
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Figure 4. Antibody activation and cytokine release. Antibodies can bind antigens resulting in activation 
of the cell and cytokine release as illustrated in the figure. 
Hematological adverse events may occur, including leucopenia and thrombocytopenia. It is 
important to monitor white blood cell, lymphocyte, and platelet counts daily. Effectively, these 
adverse events may lead to an increase in infectious complications, including cytomegalovirus 
(CMV), herpes simplex virus, Epstein-Barr virus (EBV), and varicella [45, 46]. 
2.1.2. Alemtuzumab 
2.1.2.1. Mechanism of action 
Alemtuzumab, or Campath-1H, is a monoclonal antibody to rat antihuman CD52 (Fig. 5). It is 
an IgG1 humanized molecule [47]. CD52 is present in high abundance on most lymphocytes, 
including T cell, B cells, and monocytes, but not hematopoietic precursors [48]. It effectively 
depletes T cells, and some B cells and monocytes in the circulation as well as the allograft [49]. 
 
Figure 5. Monoclonal antibodies. Monoclonal antibodies are specific and bind a single antigen as 
shown in the figure. 
2.1.2.2. Clinical applications 
Alemtuzumab has not been approved for use as an induction agent; however, this is a 
common off-label use. At this time, it is only approved to treat lymphogenous malignancies. 
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As an off-label induction agent, it’s been used with various immunosuppression regimens, 
including steroid-sparing regimens. Effectively, it depletes lymphocytes at the time of 
transplantation and last for several months to a year before the immune system is 
reconstituted [50]. Alemtuzumab is given at a dose of 30 mg or 0.3 mg/kg through a 
peripheral line over 3 hours. Sometimes 2 doses are given, although T cells are expectedly 
removed within 1 hour of initial administration [21, 49].  
Alemtuzumab depletes all T cell subsets, but has a predilection for more naïve T cells [21]. 
Memory T cell subsets may not be depleted with this therapy, but these cell types are 
especially susceptible to calcineurin inhibitors. Because of the prompt and intense depletion, 
alemtuzumab is especially appealing to use in patients with delayed graft function, as 
calcineurin inhibitor therapy can be withheld to avoid concomitant calcineurin-induced 
renal insults. 
Early studies of alemtuzumab demonstrated its efficacy as a treatment therapy for acute 
rejection; however, it was associated with significant infectious morbidity and mortality 
[47]. Patients were significantly over-immunosuppressed, especially on a triple maintenance 
therapy. More recent literature has been small studies or anecdotal data [51-53]. Because its 
efficacy is greatest against naïve T cells, its use in sensitized patients may-be limited.  
In a recent study, alemtuzumab was prospectively compared to basiliximab and rATG as an 
induction agent in patients on a steroid-sparing immunosuppressive regimen [54]. 
Alemtuzumab demonstrated lower short-term rates of acute rejection compared to 
basiliximab in patients at low-risk of developing acute rejection. At 3-years, however, the 
rates of acute rejection were no different between alemtuzumab and rATG. Patients 
receiving alemtuzumab did not experience an increased incidence of adverse events. 
2.1.2.3. Adverse effects 
Similar to rATG, alemtuzumab has been associated with cytokine release syndrome, but to a 
lesser extent. With adequate premedication with methylprednisolone, acetaminophen, and 
diphenhydramine, the cytokine release is blunted. Rash is one of the most common 
manifestations, while anaphylaxis and hypotension have been reported. It has been linked 
to the development of autoimmune thyroiditis in patients treated with alemtuzumab for 
multiple sclerosis [55]. This has also been reported in a renal transplant recipient treated 
with alemtuzumab [56]. 
2.2. Non-depleting agents 
2.2.1. Basiliximab 
2.2.1.1. Mechanism of action 
Basiliximab is a chimeric mouse-human monoclonal IgG1 antibody to CD25, the α-subunit 
of the IL-2 receptor. Basiliximab inhibition of IL-2 binding occurs through steric hindrance 
(Fig. 6). Effectively, basiliximab causes prevention of early T cell activation, as opposed to T 
cell depletion [50].  
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2.2.1.2. Clinical applications 
Basiliximab targets naïve T cells, limiting its role to induction therapy. The first dose is 
administered on the day of transplant with the final dose administered on postoperative day 
4 (20 mg per dose) via a peripheral line. Its use has been associated with decreased rates of 
acute cellular rejection compared to no formal induction agent on either triple or double 
drug immunosuppression regimens [57, 58]. Additional studies comparing basiliximab 
induction to polyclonal antibody depleting induction agents in the setting of triple 
maintenance immunosuppression regimens have shown similar outcomes with respect to 
acute rejection rates and delayed graft function [59, 60]. Basiliximab induction therapy has 
been successfully used in steroid avoidance immunosuppression regimens [61]. In the 
setting of monotherapy or calcineurin inhibitor free regimens; however, basiliximab has not 
been shown to be effective in preventing early immunologic events [62, 63]. In cases of 
excellent human leukocyte antigen (HLA)-matching (i.e. 2-haplotype matches), it’s been 
used as an effective induction agent with steroid avoidance immunosuppressive regimens 
[61]. Given the relatively mild side effect profile, basiliximab is well-tolerated in all patients, 
even those with significant cardiac or pulmonary co-morbidities. 
2.2.1.3. Adverse effects 
The side effect profile of basiliximab is relatively mild [57, 58]. Because of the lack of T cell 
activation or stimulation, cytokine release syndrome does not occur. The most serious 
adverse event is hypersensitivity, which is rare (<1%) [50]. There is no increased risk of 
infectious complications or PTLD compared to no induction therapy [64]. 
 
Figure 6. Antibody blockade. In this figure the antibody functions by blocking the antigen from binding 
to the receptor. 
2.2.2. Daclizumab 
2.2.2.1. Mechanism of Action 
Daclizumab, like basiliximab, is a CD25 antagonist; however, it is a humanized IgG1 
antibody. The CD25 molecule was the first humanized monoclonal antibody to be 
successfully targeted in the field of transplantation [65]. The mechanism of action of 
daclizumab essentially duplicates that of basiliximab. 
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2.2.2.2. Clinical applications 
Daclizumab has been shown to decrease the incidence of acute cellular rejection when 
administered as an induction agent [66, 67]. Given the favorable side effect profile, it is well 
tolerated, irrespective of co-morbid conditions. The main disadvantage of daclizumab, as 
compared to basiliximab, is that it is more costly and requires repeated administrations [50]. 
Given the low demand for the medication, it has been discontinued by the manufacturer. 
2.2.2.3. Adverse effects 
The generally favorable side effect profile resembles that of basiliximab. Cytokine release is 
not typically associated with this agent [66, 67]. Like basiliximab, the risk of infectious 
complications or PTLD is not significantly increased with use [64]. 
3. Desensitizing agents 
3.1. Rituximab 
3.1.1. Mechanism 
Rituximab is a monoclonal chimeric antibody to the CD20 molecule. CD20 is a glycoprotein 
on the cell surface of circulating, mature B cells. Rituximab effectively depletes CD20+ cells 
from the circulation by inducing apoptosis [68]. These cells are precursors to antibody-
producing plasma cells, and their role in transplantation is only partially characterized. 
They may play a role in acute rejection, as B cells can act as antigen presenting cells. 
3.1.2. Applications 
Rituximab is approved for use in various lymphomas, leukemias, PTLD, and rheumatoid 
arthritis [50, 69]. Peripheral veins can be used for administration and dosing is dependent on 
the indication. A recent study examining the role of rituximab as an induction agent found 
no benefit compared to placebo [70]. However, it does play a role as a desensitizing agent in 
patients with preformed donor specific antibodies (DSA), in conjunction with total 
plasmapheresis and/or intravenous immunoglobulin (IVIG) [71, 72]. 
Additionally, it has been used to aid in transplanting across blood group barriers in donor 
recipient pairs and in patients with positive crossmatches following antibody elimination. 
Rituximab is increasingly being used to treat episodes of vascular rejection and antibody 
mediated rejections [73, 74]. Finally, rituximab is a proven and effective agent in the 
treatment of PTLD [75]. Administration does not replace immunosuppression reduction or 
chemotherapy, but rather supplements the other modalities. 
3.1.3. Adverse effects 
Rituximab is generally well-tolerated with minimal side effects. Anaphylaxis remains a 
theoretical concern, as is the case with most agents. Reports on infectious complications 
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related to rituximab have been variable [76-78]. In some instances there was no difference in 
bacterial, viral, or fungal infections in kidney transplant recipients treated with rituximab, 
however, this remains controversial. 
3.2. Bortezomib 
3.2.1. Mechanism 
Bortezomib is a proteasomal inhibitor that causes apoptosis of plasma cells. It binds the 26S 
subunit of the proteasome [79]. Proteasome inhibition ultimately leads to apoptosis during 
mitosis. Bortezomib selectively causes apoptosis in CD138+ plasma cells [80]. Additionally, 
Bortezomib may block T cell cycling and decrease the number of circulating B cells by 
reducing bone marrow levels of IL-6 [81]. 
3.2.2 .Applications 
Bortezomib has not been approved for use in kidney transplantation; however, it has been 
used in sensitized patients [80]. Bortezomib has been successfully used to decrease DSA 
levels, which may play a role in acute antibody-mediated rejection (AMR) Induction 
Therapy in Renal Transplant Recipients [82]. Furthermore, in vivo data has demonstrated a 
decrease in the percentage of bone marrow plasma cells, antibody production, and 
allospecificities of plasma cells in bone marrow aspirates of patients treated with bortezomib 
i in the setting of AMR [80]. 
3.2.3. Adverse events 
Bortezomib has been associated with various side effects. Although gastrointestinal side 
effects are the most common, peripheral neuropathy has also been reported, especially in 
patients with a pre-existing history of neuropathy [79]. Moreover, myelosuppression and 
shingles has been reported. 
3.3. Intravenous Immunoglobulin (IVIG) 
3.3.1. Mechanism 
Intravenous immunoglobulin, or IVIG, is pooled polyclonal antibodies from different 
human donors. These are high-dose human IgG fractions with a wide range of specificities. 
These are non-T cell specific formulations and have no specific cell targets [83]. It is able to 
bind activated complement components or even inhibit complement activation [84]. IVIG 
may also modulate the alloimmune response by binding to the Fc receptor of antigen-
presenting cells, effectively quelling the alloimmune response [85]. 
3.3.2. Applications 
Despite the inability to deplete T cells, IVIG is an effective treatment of acute cellular 
rejection. Early studies showed that IVIG was as effective as OKT3 in reversing steroid 
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resistant acute rejection episodes [86]. In the setting of antibody-mediated rejection, IVIG 
has been shown to be beneficial when used in conjunction with plasmapheresis and/or 
rituximab [87-88]. As a desensitization agent alone, no study has demonstrated a clear 
benefit [88, 89]. Definitive reduction of antibody was not shown and a survival advantage 
was not evident. 
3.3.3. Adverse effects 
The side-effect profile of IVIG increases with dosing. High-dose IVIG is associated with 
more infusion-related complications, such as headache, thrombotic incidents, hemolysis, 
bronchospasms, osmotic nephropathy, or even aseptic meningitis [83, 90]. Sucrose-based 
and high osmolality products have a higher risk of developing osmotic nephropathy as 
opposed to other preparation. Nevertheless, it is typically well-tolerated, especially at lower 
doses and most patients report only headache. 
4. Maintenance immunosuppression regimens 
4.1. Historical background 
The initial transplant armamentarium consisted only of azathioprine and steroids for 
maintenance immunosuppression in renal transplantation until the 1980’s, when the first 
calcineurin inhibitor, cyclosporine became available. Over the next 20 years, azathioprine 
had been largely replaced by mycophenolate (MMF), an antiproliferative agent. Standard 
therapy in most modern immunosuppression regimens now consists of a calcineurin 
inhibitor, mycophenolate, with or without steroid maintenance. 
Minimizing global immunosuppression in the modern era of transplantation has become an 
important goal. The use of induction therapy has allowed for steroid avoidance 
immunosuppression regimens. The goal of steroid avoidance immunosuppression is to 
decrease the negative cardiovascular profile associated with long-term administration of 
steroids. Specifically, steroid-free regimens should decrease the negative effects on blood 
pressure control as well serum glucose and lipid metabolism [91]. Moreover, the leading 
cause of death in kidney transplant patients is cardiovascular events [92]. 
4.2. Steroid maintenance versus withdrawal 
Advocates of steroid-maintenance regimens suggest that steroids may allow for lower doses 
of calcineurin inhibitors, such as cyclosporine or tacrolimus. Moreover, steroids may 
decrease the incidence of nephrotoxicity perioperatively. However, there has been 
insufficient data to support either conclusion [93]. 
The effectiveness of steroid-withdrawal and cyclosporine-based therapy has been clearly 
associated with timing. Early studies of cyclosporine-based regimens demonstrated that 
cessation of steroids prior to the 6 month period post-transplantation increased the risk of 
acute rejection [94]. Furthermore, a meta-analysis of seven randomized-controlled trials of 
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steroid avoidance and/or withdrawal demonstrated an increased risk of acute rejection with 
steroid avoidance or early withdrawal (most steroids were withdrawn in the first 3 months 
post-transplant) [95]. However, patient and graft survival were not adversely affected in the 
meta-analysis.  
The ability to withdrawal steroids appears to be better with tacrolimus-based 
immunosuppression regimens. An early report by Shapiro et al. demonstrated that patients 
receiving tacrolimus and steroid-sparing immunosuppression had excellent early and 
intermediate-term patient and graft survival compared to kidney transplant recipients 
receiving standard steroid-maintenance immunosuppression [96]. Later, various 
randomized-controlled trials were undertaken to assess the initial outcomes. A meta-
analysis of six randomized, controlled-trials comparing a calcineurin inhibitor-based 
immunosuppression regimen with MMF demonstrated a slightly increased risk of acute 
rejection once steroids were discontinued; however, this did not affect the incidence of graft 
failure [97]. Shortly thereafter, a randomized trial from Europe assigned low immunologic 
risk patients to receive either triple immunosuppression with tacrolimus, MMF, and 
steroids, a tacrolimus-based steroid withdrawal regimen, or a tacrolimus-based steroid-
maintenance regimen without MMF [98]. At 6 months, the incidence of acute rejection was 
not different between the groups. Furthermore, the steroid withdrawal group benefited 
from an improved lipid profile. Kumar et al. reported on a series of 300 kidney transplant 
recipients receiving basiliximab induction therapy followed by steroid maintenance or 
withdrawal at 2 days post-transplant [99]. Maintenance therapy for all patients consisted of 
a calcineurin inhibitor and MMF or sirolimus. At 3 years, the incidence of biopsy-proven 
acute rejection, patients and graft survival, chronic allograft nephropathy, or graft function 
was not significantly different. Moreover, the steroid withdrawal group benefited from a 
lower rate of new-onset diabetes after transplantation. 
Successful avoidance of steroids is contingent upon the use of calcineurin inhibitors. In 2006 
Gelens and colleagues performed a single-center, randomized, trial of three parallel groups, 
which were: tacrolimus and sirolimus (group one), tacrolimus and MMF (group two), and 
sirolimus and MMF with daclizumab induction [100]. During an interim analysis when 50% 
of the patients were included, group one had a significantly increased rejection free survival 
(82%) compared to group three (34%, P=0.03) and between groups one and two (tacrolimus-
based, 76%) and group three (34%, P=0.04). The study was halted prematurely. Despite the 
current armamentarium of antibody-depleting medications, steroid withdrawal seems 
feasible only with a calcineurin inhibitor-based regimen. 
4.3. Induction therapy and steroid withdrawal 
The possible minimization of maintenance immunosuppression has been studied using 
basiliximab and rATG without compromising allograft outcomes. In the Astellas Steroid 
Withdrawal Study, patients assigned to the steroid-withdrawal arm and treated with rATG 
experienced a lower cumulative incidence of biopsy-proven acute rejection at 5 years 
compared to patients treated with basiliximab [101]. Selection bias; however, may have 
marred this study, given that the investigators selected which antibody induction agent was 
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used. Our transplant center’s experience utilizing induction therapy to enable steroid 
withdrawal has been very successful in a diverse population, using rATG in the majority of 
patients [102] and basiliximab in well-matched living donor recipients [61]. In a study by 
Cantarovich et al., patients administered rATG and steroid-maintenance 
immunosuppression had significantly lower acute rejection rates compared to patients on a 
steroid-free immunosuppression regimen, although the incidence of malignancy, de novo 
diabetes, and hyperlipidemia were higher in steroid-maintenance group [103]. Patient 
survival, graft survival, and infection rates were not significantly different between the two 
groups at 1 year.  
Alemetuzumab and steroid-free regimens have been compared to both basiliximab and 
rATG. In the study by Hanaway et al., acute rejection rates were relatively low in low-risk 
patients receiving alemtuzumab compared to basiliximab, although the reduced 
immunologic risk profile of alemtuzumab was not evident in high risk patients treated with 
rATG [54]. The overall rate of adverse events with alemtuzumab was similar to that of 
basiliximab or rATG over the 3 year study period (53% versus 50%, respectively; p=0.46). 
Moreover, the rate of cardiovascular events of all alemtuzumab treated patients compared 
to basiliximab or rATG was also similar (7% versus 10%, respectively; p=0.26), although the 
similarity was less evident in the high-risk immunologic group treated with rATG 
compared to alemtuzumab (12% versus 3%, respectively; p=0.06). Cai et al. analyzed the 
United Network for Organ Sharing registry and found that recipients of alemtuzumab in 
conjunction with steroid-maintenance therapy had the lowest risk of graft failure, while 
patients administered an interleukin-2 receptor antagonist on a steroid-free 
immunosuppression regimen had the highest risk of graft failure [104]. In a single-center, 
open-label randomized trial of 200 kidney transplant recipients, low dose dual induction 
therapy of rATG and daclizumab was compared to lose dose dual therapy of rATG and 
alemtuzumab in patients maintained on steroid-free maintenance immunosuppression 
[105]. Patient and graft survival rates as well as acute rejection and infectious complication 
rates were not significantly different. In addition, no patient developed post-transplant 
lymphoproliferative disorder. 
5. New and experimental agents 
5.1. Siplizumab (MEDI-507) 
Originally described as BTI-322, siplizumab is a monoclonal humanized antibody to CD2. It is 
an IgG1k molecule derived from rat [106]. CD2, or lymphocyte function-associated antigen-2 
(LFA-2) is an important T cell adhesion molecule that binds to CD58, or LFA-3. This is a 
transmembrane signal transduction molecule that facilitates T cell receptor binding. Early 
studies examined the use of siplizumab as an induction agent and treatment modality for 
acute rejection in solid organ transplantation as well as graft-versus-host disease [106, 107]. 
The first human study of siplizumab demonstrated the safety and feasibility in kidney 
transplantation, as compared to placebo; however, current endeavors are focused on 
investigating its use in nonmyeloablative conditioning regimens to achieve mixed chimerism 
[106, 108, 109]. In addition, it is being investigated for the treatment of plaque psoriasis [110]. 
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5.2. Alefacept 
Alefacept is a dimeric fusion protein (Fig.7) constituted from LFA-3 and the human Fc 
portion of IgG1. Studies have demonstrated inhibition of T cell proliferation and depletion 
of effector memory T cells [111, 112]. Currently, alefacept is approved to treat plaque 
psoriasis. Preclinical studies in nonhuman primates have demonstrated a survival benefit of 
alefacept, when used in conjunction with costimulatory blockade, but not alone; however in 
human trials have never shown a benefit [113]. 
 
Figure 7. Mimicry. In this figure, the antibody is fused with a protein structural similar to the intended 
antigen, which can serve as activating or inhibitory. 
5.3. Costimulatory blockade 
5.3.1. Abatacept 
Abatacept is a recombinant cytotoxic T-lymphocyte antigen 4 (CTLA4) fused with the Fc 
portion of IgG1 [114, 115]. Animal models demonstrated its ability to delay or even prevent 
the onset of allograft rejection, which is comparable to basiliximab and some polyclonal 
antibody therapies [114-116]. It has been approved for treatment of rheumatoid arthritis 
[117, 118]. Further investigations of this medication are not currently under development. 
5.3.2. Belatacept 
Belatacept is the improved version of abatacept, providing selective blockade of T cell 
activation as a fusion protein. Two amino acids have been changed to improve dissociation 
rates when binding to CD80 and CD86 [119, 120]. In the phase II trial comparing belatacept 
to cyclosporine, acute rejection rates were similar, while allograft function was significantly 
improved in patients receiving belatacept [119]. In the phase III trial of kidney 
transplantation, patients receiving belatacept experienced improved allograft function at 12 
months; however, acute rejection rates and severity of acute rejection episodes were 
significantly higher in the belatacept arm of the study. Additionally, the incidence of PTLD 
was greater in patients receiving belatacept [120]. An additional study investigating the 
efficacy of belatacept in kidney transplantation of extended criteria donors demonstrated 
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similar results, with a predilection towards central nervous system (CNS) forms of PTLD 
[121]. The novelty of costimulation blockade is the ability to avoid calcineurin inhibitors, 
especially in allografts at increased risk of delayed graft function. Belatacept has recently 
been approved for the prophylaxis of organ rejection in adult patients receiving a kidney 
transplant, in combination with basiliximab induction, mycophenolate mofetil, and 
corticosteroids [122]. Current recommendations include using it only in patients who are 
EBV seropositive; however, patients should be monitored for an increased risk of infectious 
complications and Progressive Multifocal Leukoencephalopathy. 
5.4. Eculizumab 
Recently, a new medication called eculizumab has emerged as a humanized monoclonal 
antibody to complement component 5 (C5) to mediate complement-mediated injury [123]. 
Blocking complement activation, especially the last step of the complement cascade, has 
important implications in kidney transplantation. However, the role of eculizumab appears 
to be more applicable to cases of clear complement-mediated destruction, such as antibody-
mediated rejection and desensitization protocols [124]. Furthermore, the logistics of 
administration may further hinder its’ use as a maintenance immunosuppression agent, as it 
must be administered biweekly or weekly intravenously at least for the first 1-2 months 
upon initiation of therapy. Currently, it is only approved for the treatment of patients with 
paroxysmal nocturnal hemoglobinuria [123]. 
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